Treatment Group | Time Post-Exposure | AII | BI | TBI | BHH |
|---|
Gr20 | 7Â day | - |
0.17 (1/6) |
1.7 (6/6) |
1.0 (5/6) |
Gr5 | 7Â day | - | - |
1.0 (5/6) | - |
Gr1 | 7Â day | - | - | - | - |
CB | 7Â day | - | - |
0.5 (3/6) |
0.17 (1/6) |
Gr20 | 1Â month |
0.17 (1/6) | - |
0.7 (4/6) |
0.7 (4/6) |
Gr5 | 1Â month | - | - |
0.7 (2/6) |
0.5 (3/6) |
Gr1 | 1Â month | - | - | - | - |
CB | 1Â month | - | - | - | - |
Gr20 | 2Â months |
-
| - |
0.7 (4/6) |
0.83 (5/6) |
Gr5 | 2Â months |
0.3 (2/6) | - | - |
0.5 (3/6) |
Gr1 | 2Â months | - | - | - | - |
CB | 2Â months | - | - | - | - |
- Lung tissue was analyzed for alveolar interstitial inflammation (AII), bronchiolar inflammation (BI), terminal bronchiolar inflammation (TBI), and bronchiolar hypertrophy or hyperplasia (BHH), type II cell hypertrophy, BALT, lipidosis, fibrosis (n = 6 per group per time point). Severity was scored as 0-5: 0 = normal, 1 = minimal/slight, 2 = mild, 3 = moderate, 4 = marked, and 5 = severe. Data are presented as means in bold with incidence (number of animals with a positive score per total animals) in parentheses. No changes in type II cell hypertrophy, BALT, lipidosis, or fibrosis were noted with the exception of one 1 animal from the Gr20 group at 2 months that had one fibrotic focal area scored as 1
